- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04858607
Humoral and Cellular Immune Response to COVID-19 Vaccines in Immunocompromised and Healthy Individuals (CoVVac)
Humoral and Cellular Immune Response to COVID-19 Vaccines in Immunocompromised and Healthy Individuals - The CoVVac Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Martin Stradner, Prof.
- Phone Number: 81794 +43316385
- Email: Martin.stradner@medunigraz.at
Study Locations
-
-
-
Graz, Austria
- Medical University of Graz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Noninfectious immunocompetent participants (i.e., healthy participants) as determined by medical history and clinical judgement.
or
- Patients with primary immunodeficiencies or
- Patients with B-cell depleting therapy due to autoimmune disease or
Patients with benign and malignant hematological diseases receiving specific Treatments with known immunosuppressive effects including cytotoxic agents, systemic corticosteroids, monoclonal antibodies and targeted therapies.
or
Patients with active hematological diseases and secondary immunoglobulin deficiency (e.g. chronic lymphatic leukemia, MM) currently not receiving specific treatment.
or
Patients >3 months but <12 months after autologous HSCT (hematopoietic stem cell transplantation).
or
- Patients >3 months but <12 months after allogeneic HSCT. or
Recipients of HSCT >12 months after allogeneic HSCT but under immunosuppressive therapy.
or
- Patients with chronic GvHD (graft-versus-host disease) and persistent immunodeficiency.
Exclusion Criteria:
Healthy participants
- Presence of diseases or therapies that are likely to interfere with the immune response to vaccination.
- Presence of a disease requiring change in therapy during 4 weeks before enrollment.
- Any contraindications to the vaccine planned to receive as listed in the product characteristics.
- Lack of willingness to undergo serial blood draws and attend follow-up appointments.
- Women who are pregnant or breastfeeding.
- Previous vaccination with any coronavirus vaccine.
- Persons who are not willing to sign the informed consents (biobank informed consent and study specific informed consent).
Immunodeficient participants
- Patients with hematological diseases within three months from B-cell-depleting immunotherapy (rituximab, ofatumumab, obinutuzumab, blinatumomab, CAR-T cells (Chimeric Antigen Receptor).
- Patients with hematological malignancies in remission and >12 months after end of specific therapy.
- Patients within three months from HSCT.
- Any contraindications to the vaccine planned to receive as listed in the product characteristics.
- Lack of willingness to undergo serial blood draws and attend follow-up appointments.
- Women who are pregnant or breastfeeding.
- Previous vaccination with any coronavirus vaccine (exception: if serum prior to vaccination is available from the biobank).
- Patients who are not willing to sign the informed consents (biobank informed consent and study specific informed consent).
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Immunocompromised individuals
Patients with primary or secondary immunodeficiency planning on vaccination against SARS CoV-2 according to the Austrian vaccination plan.
|
Serology, immune status, T cell immunity, and T cell aging.
Antibody tests
|
Healthy individuals
Healthy people planning on vaccination against SARS CoV-2 according to the Austrian vaccination plan.
|
Serology, immune status, T cell immunity, and T cell aging.
Antibody tests
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The levels of anti-SARS-CoV-2 spike protein humoral immune response.
Time Frame: At day 21-28 after the second vaccination
|
The levels of anti-SARS-CoV-2 (severe acute respiratory syndrome-Covid Virus) spike protein humoral immune response measured by SARS-CoV-2 antigen-binding Ig assay comparing immunocompromised patients to healthy controls.
|
At day 21-28 after the second vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Seroconversion
Time Frame: 6, 12 and 24 months after vaccination.
|
Change of Seroconversion measured by SARS-CoV-2 antigen-binding Ig assay 6, 12 and 24 months after vaccination.
|
6, 12 and 24 months after vaccination.
|
Concentrations of recombinant S protein-binding IgG (immunoglobulin G)
Time Frame: At day 21-28 as well as 12 and 24 months after the second vaccination.
|
Change of Concentrations of recombinant S protein-binding IgG after second vaccination in comparison to response after first vaccination.
|
At day 21-28 as well as 12 and 24 months after the second vaccination.
|
Concentrations of secretory and serum IgA in comparison to IgG and IgM (immunoglobulin M)
Time Frame: At day 21-28 as well as 12 and 24 months after the second vaccination.
|
Change of Concentrations of secretory and serum IgA in comparison to IgG and IgM after second vaccination in immunocompromised, in recovered individuals and in healthy controls.
|
At day 21-28 as well as 12 and 24 months after the second vaccination.
|
IFNγ production of T cells
Time Frame: At day 21-28 as well as 12 and 24 months after the second vaccination.
|
Change of IFNγ (Interferone gamma) production of T cells after SARS-CoV-2 antigen exposure, measured by FACS (fluorescence-activated cell sorter) and ELISpot.
|
At day 21-28 as well as 12 and 24 months after the second vaccination.
|
Cross-reactive antibodies predicting the response to COVID-19 vaccinations
Time Frame: At day 21-28 as well as 12 and 24 months after the second vaccination.
|
Identification of parameters predicting the response to COVID-19 vaccinations: prior CoV infection (cross-reactive antibodies).
Evaluation of the influence of previous infections caused by endemic CoV (proven through cross-reactive antibodies) on the vaccine response in immunocompromised individuals and in COVID-19 recovered individuals compared to controls.
|
At day 21-28 as well as 12 and 24 months after the second vaccination.
|
Quantitative immunoglobulins predicting the response to COVID-19 vaccinations
Time Frame: At day 21-28 as well as 12 and 24 months after the second vaccination.
|
Identification of parameters predicting the response to COVID-19 vaccinations: quantitative immunoglobulins.
|
At day 21-28 as well as 12 and 24 months after the second vaccination.
|
B cell subsets predicting the response to COVID-19 vaccinations
Time Frame: At day 21-28 as well as 12 and 24 months after the second vaccination.
|
Identification of parameters predicting the response to COVID-19 vaccinations: B cell subsets.
|
At day 21-28 as well as 12 and 24 months after the second vaccination.
|
T cell subsets predicting the response to COVID-19 vaccinations
Time Frame: At day 21-28 as well as 12 and 24 months after the second vaccination.
|
Identification of parameters predicting the response to COVID-19 vaccinations: T cell subsets.
|
At day 21-28 as well as 12 and 24 months after the second vaccination.
|
T cell aging predicting the response to COVID-19 vaccinations
Time Frame: 60-0 days before first vaccination.
|
Identification of parameters predicting the response to COVID-19 vaccinations: T cell aging (TCR diversity, telomere length, TREC levels).
|
60-0 days before first vaccination.
|
Occurence of neutralizing antibodies by means of SARS-CoV-2 neutralizing assays.
Time Frame: At day 21-28 as well as 12 and 24 months after the second vaccination.
|
Neutralizing capacity of antibodies in respect of different SARSCoV-2 variants.
|
At day 21-28 as well as 12 and 24 months after the second vaccination.
|
Correlation of diet and body fat with seroconversion
Time Frame: At day 21-28 and 12 months after the second vaccination.
|
Correlation of diet and body fat with seroconversion after second vaccination.
|
At day 21-28 and 12 months after the second vaccination.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CoVVac
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Blood sample
-
Medical University of WarsawCompletedArthroplasty | Platelet Aggregation | Methylmethacrylate EmbolismPoland
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
Meir Medical CenterCompleted
-
First Affiliated Hospital of Zhejiang UniversityRecruitingComplication | Hematologic Malignancy | Hematopoietic Stem Cell Transplantation | Chronic Graft-versus-host-diseaseChina
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceRecruitingImmune Thrombocytopenia | Autoimmune Hemolytic Anemia | Autoimmune NeutropeniaFrance
-
University Hospital, ToursCompletedMetastatic Prostate Cancer | Circulating Tumor DNAFrance
-
University Hospital, BordeauxActive, not recruitingSystemic Lupus Erythematosus | Systemic SclerodermaFrance
-
University Hospital, BordeauxCompletedRenal Function Disorder | Chronic Renal Diseases
-
University Hospital, ToursNot yet recruitingRenal Transplant | ConversionFrance